Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Reward | 18 | 2022 | 970 | 3.160 |
Why?
|
Gambling | 7 | 2017 | 258 | 2.100 |
Why?
|
Behavior, Addictive | 13 | 2022 | 462 | 2.040 |
Why?
|
Cocaine-Related Disorders | 12 | 2008 | 461 | 2.000 |
Why?
|
Naltrexone | 8 | 2020 | 316 | 1.530 |
Why?
|
Benzodiazepines | 5 | 2017 | 1130 | 1.330 |
Why?
|
Pituitary-Adrenal System | 5 | 2024 | 549 | 1.010 |
Why?
|
Stress Disorders, Post-Traumatic | 8 | 2022 | 4569 | 0.990 |
Why?
|
Opioid-Related Disorders | 8 | 2022 | 2152 | 0.920 |
Why?
|
Cocaine | 6 | 2008 | 958 | 0.920 |
Why?
|
Schizophrenia | 17 | 2017 | 6925 | 0.870 |
Why?
|
Hypothalamo-Hypophyseal System | 5 | 2024 | 698 | 0.850 |
Why?
|
Pain | 8 | 2018 | 5074 | 0.820 |
Why?
|
Narcotic Antagonists | 7 | 2020 | 585 | 0.810 |
Why?
|
Motivation | 7 | 2017 | 2006 | 0.780 |
Why?
|
Hydrocortisone | 10 | 2005 | 1815 | 0.750 |
Why?
|
Antipsychotic Agents | 11 | 2017 | 3066 | 0.720 |
Why?
|
Deoxyglucose | 7 | 2004 | 333 | 0.660 |
Why?
|
Brain | 25 | 2021 | 27049 | 0.610 |
Why?
|
Hallucinogens | 1 | 2021 | 197 | 0.610 |
Why?
|
Stress, Physiological | 4 | 2024 | 1400 | 0.610 |
Why?
|
Beauty | 2 | 2009 | 41 | 0.580 |
Why?
|
Cerebrum | 1 | 2018 | 132 | 0.570 |
Why?
|
Avoidance Learning | 1 | 2018 | 248 | 0.560 |
Why?
|
Glucose Tolerance Test | 2 | 2017 | 1178 | 0.550 |
Why?
|
Substance-Related Disorders | 7 | 2022 | 4416 | 0.540 |
Why?
|
Unconsciousness | 1 | 2018 | 250 | 0.520 |
Why?
|
Adrenocorticotropic Hormone | 5 | 2003 | 616 | 0.520 |
Why?
|
Stress, Psychological | 6 | 2024 | 4475 | 0.510 |
Why?
|
Psychotic Disorders | 5 | 2017 | 3206 | 0.490 |
Why?
|
Clozapine | 7 | 2006 | 506 | 0.450 |
Why?
|
Awareness | 1 | 2018 | 647 | 0.440 |
Why?
|
Nerve Net | 5 | 2013 | 2279 | 0.430 |
Why?
|
Norepinephrine | 5 | 2004 | 898 | 0.420 |
Why?
|
Comorbidity | 4 | 2022 | 10491 | 0.410 |
Why?
|
Yohimbine | 1 | 2012 | 62 | 0.400 |
Why?
|
Consciousness | 1 | 2018 | 601 | 0.400 |
Why?
|
Appetite Depressants | 1 | 2012 | 108 | 0.390 |
Why?
|
Face | 2 | 2009 | 1019 | 0.380 |
Why?
|
Brain Mapping | 4 | 2018 | 6599 | 0.370 |
Why?
|
Sucrose | 1 | 2011 | 158 | 0.370 |
Why?
|
Amygdala | 4 | 2016 | 1353 | 0.350 |
Why?
|
Dopamine | 10 | 2022 | 1603 | 0.340 |
Why?
|
Dopamine Agonists | 2 | 2018 | 352 | 0.330 |
Why?
|
Emotions | 4 | 2021 | 2735 | 0.320 |
Why?
|
Blood Glucose | 3 | 2017 | 6378 | 0.320 |
Why?
|
Analgesics, Opioid | 8 | 2022 | 3790 | 0.290 |
Why?
|
Delayed-Action Preparations | 5 | 2020 | 961 | 0.290 |
Why?
|
Suicide | 2 | 2021 | 1598 | 0.290 |
Why?
|
Antimetabolites | 2 | 2004 | 128 | 0.280 |
Why?
|
Heroin Dependence | 3 | 2015 | 172 | 0.280 |
Why?
|
Psychiatric Status Rating Scales | 10 | 2017 | 6018 | 0.270 |
Why?
|
Adult | 55 | 2021 | 220718 | 0.260 |
Why?
|
Combat Disorders | 1 | 2008 | 301 | 0.260 |
Why?
|
Prolactin | 2 | 2005 | 624 | 0.250 |
Why?
|
Humans | 91 | 2024 | 760239 | 0.240 |
Why?
|
Risperidone | 3 | 2002 | 380 | 0.240 |
Why?
|
Analysis of Variance | 8 | 2012 | 6230 | 0.240 |
Why?
|
Cues | 5 | 2015 | 874 | 0.240 |
Why?
|
Energy Intake | 1 | 2012 | 2133 | 0.240 |
Why?
|
Dopamine Uptake Inhibitors | 4 | 2002 | 297 | 0.230 |
Why?
|
Dopamine Antagonists | 5 | 2002 | 288 | 0.230 |
Why?
|
Culture | 1 | 2008 | 623 | 0.230 |
Why?
|
Psychomotor Performance | 2 | 2013 | 1880 | 0.230 |
Why?
|
Male | 62 | 2021 | 359943 | 0.220 |
Why?
|
Personal Satisfaction | 1 | 2008 | 642 | 0.220 |
Why?
|
Behavior | 4 | 2019 | 540 | 0.220 |
Why?
|
Catecholamines | 1 | 2004 | 386 | 0.220 |
Why?
|
Growth Hormone | 1 | 2005 | 568 | 0.210 |
Why?
|
Pilot Projects | 9 | 2021 | 8610 | 0.210 |
Why?
|
Sympathetic Fibers, Postganglionic | 1 | 2002 | 14 | 0.210 |
Why?
|
Neurobiology | 2 | 2018 | 137 | 0.210 |
Why?
|
Dose-Response Relationship, Drug | 8 | 2017 | 10758 | 0.200 |
Why?
|
Sex Characteristics | 2 | 2011 | 2632 | 0.200 |
Why?
|
Solitary Nucleus | 1 | 2022 | 54 | 0.200 |
Why?
|
Female | 56 | 2021 | 391766 | 0.200 |
Why?
|
Vasopressins | 1 | 2003 | 351 | 0.200 |
Why?
|
Methoxyhydroxyphenylglycol | 2 | 2001 | 93 | 0.200 |
Why?
|
Serotonin Antagonists | 1 | 2002 | 144 | 0.200 |
Why?
|
Weight Gain | 1 | 2012 | 2346 | 0.200 |
Why?
|
Double-Blind Method | 11 | 2013 | 12314 | 0.190 |
Why?
|
Adipose Tissue | 1 | 2013 | 3305 | 0.190 |
Why?
|
Patient Acceptance of Health Care | 3 | 2016 | 3190 | 0.190 |
Why?
|
Epinephrine | 2 | 2004 | 792 | 0.190 |
Why?
|
Peripheral Nervous System | 1 | 2002 | 151 | 0.190 |
Why?
|
Analgesics | 2 | 2021 | 1067 | 0.180 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 3 | 2016 | 1988 | 0.180 |
Why?
|
Depressive Disorder | 3 | 2006 | 3728 | 0.180 |
Why?
|
Visual Perception | 2 | 2008 | 1379 | 0.170 |
Why?
|
Substance Withdrawal Syndrome | 2 | 2002 | 625 | 0.170 |
Why?
|
Eating | 1 | 2006 | 1535 | 0.160 |
Why?
|
Triglycerides | 2 | 2017 | 2455 | 0.160 |
Why?
|
Self Disclosure | 1 | 2000 | 249 | 0.160 |
Why?
|
Psychiatry | 1 | 2011 | 1690 | 0.150 |
Why?
|
Inappropriate Prescribing | 1 | 2021 | 212 | 0.150 |
Why?
|
Mental Recall | 1 | 2004 | 1213 | 0.150 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 5834 | 0.150 |
Why?
|
Testosterone | 2 | 2001 | 2470 | 0.150 |
Why?
|
Insulin Resistance | 3 | 2017 | 3954 | 0.150 |
Why?
|
Severity of Illness Index | 8 | 2011 | 15818 | 0.140 |
Why?
|
Middle Aged | 21 | 2021 | 220307 | 0.140 |
Why?
|
Autonomic Nervous System | 1 | 2022 | 701 | 0.140 |
Why?
|
Magnetic Resonance Imaging | 14 | 2018 | 36351 | 0.140 |
Why?
|
Adrenal Cortex | 1 | 1997 | 134 | 0.130 |
Why?
|
Affect | 3 | 2011 | 1483 | 0.130 |
Why?
|
Injections, Intramuscular | 2 | 2020 | 554 | 0.130 |
Why?
|
Drug-Seeking Behavior | 1 | 2016 | 46 | 0.130 |
Why?
|
Rare Diseases | 1 | 2021 | 621 | 0.130 |
Why?
|
Maternal Behavior | 1 | 2017 | 307 | 0.120 |
Why?
|
Homovanillic Acid | 3 | 2004 | 75 | 0.120 |
Why?
|
Corticotropin-Releasing Hormone | 1 | 2016 | 360 | 0.120 |
Why?
|
Infusions, Intravenous | 4 | 2005 | 2217 | 0.120 |
Why?
|
Marijuana Abuse | 2 | 2008 | 411 | 0.110 |
Why?
|
Methylphenidate | 3 | 2006 | 488 | 0.110 |
Why?
|
Attention | 1 | 2004 | 2390 | 0.110 |
Why?
|
Body Mass Index | 3 | 2017 | 12917 | 0.110 |
Why?
|
Veterans | 1 | 2008 | 2641 | 0.110 |
Why?
|
Pituitary Gland | 1 | 1997 | 637 | 0.110 |
Why?
|
Statistics as Topic | 2 | 2016 | 2357 | 0.110 |
Why?
|
Interview, Psychological | 1 | 2017 | 809 | 0.110 |
Why?
|
Neostriatum | 3 | 2000 | 246 | 0.110 |
Why?
|
Anesthesia, General | 1 | 2001 | 1173 | 0.110 |
Why?
|
Insulin | 1 | 2008 | 6589 | 0.110 |
Why?
|
Mental Disorders | 2 | 2011 | 6828 | 0.110 |
Why?
|
Community Mental Health Services | 1 | 2016 | 392 | 0.110 |
Why?
|
Product Labeling | 1 | 2013 | 76 | 0.110 |
Why?
|
Neural Pathways | 4 | 2016 | 3047 | 0.110 |
Why?
|
Event-Related Potentials, P300 | 1 | 2013 | 149 | 0.100 |
Why?
|
Hydroxyindoleacetic Acid | 2 | 2003 | 93 | 0.100 |
Why?
|
Cerebrovascular Circulation | 2 | 2002 | 2728 | 0.100 |
Why?
|
Drug Resistance | 1 | 2018 | 1597 | 0.100 |
Why?
|
Regression Analysis | 3 | 2017 | 6336 | 0.100 |
Why?
|
Social Stigma | 1 | 2019 | 768 | 0.100 |
Why?
|
Progesterone | 1 | 1997 | 742 | 0.100 |
Why?
|
Adrenergic alpha-2 Receptor Antagonists | 1 | 2012 | 18 | 0.100 |
Why?
|
Cross-Over Studies | 3 | 2011 | 2070 | 0.100 |
Why?
|
Liver Function Tests | 1 | 2013 | 522 | 0.100 |
Why?
|
Cerebellar Diseases | 1 | 2014 | 220 | 0.100 |
Why?
|
Appetite Regulation | 1 | 2012 | 84 | 0.100 |
Why?
|
Injections, Intraperitoneal | 1 | 2012 | 412 | 0.100 |
Why?
|
Taste Perception | 1 | 2011 | 37 | 0.100 |
Why?
|
Arousal | 1 | 2017 | 1161 | 0.090 |
Why?
|
Amphetamine | 3 | 2002 | 224 | 0.090 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 3 | 2006 | 3702 | 0.090 |
Why?
|
Metabolic Clearance Rate | 2 | 2002 | 361 | 0.090 |
Why?
|
Homeostasis | 2 | 2022 | 3318 | 0.090 |
Why?
|
Dihydroxyphenylalanine | 2 | 2001 | 74 | 0.090 |
Why?
|
Educational Status | 1 | 2017 | 2516 | 0.080 |
Why?
|
Migraine Disorders | 1 | 2021 | 1697 | 0.080 |
Why?
|
Receptors, N-Methyl-D-Aspartate | 4 | 1999 | 894 | 0.080 |
Why?
|
Rats, Wistar | 1 | 2012 | 1844 | 0.080 |
Why?
|
Analgesia | 1 | 2013 | 460 | 0.080 |
Why?
|
Outpatients | 1 | 2016 | 1596 | 0.080 |
Why?
|
Ketamine | 3 | 1999 | 519 | 0.080 |
Why?
|
Tomography, Emission-Computed | 6 | 2002 | 1122 | 0.070 |
Why?
|
Affective Symptoms | 1 | 2011 | 417 | 0.070 |
Why?
|
Random Allocation | 1 | 2012 | 2388 | 0.070 |
Why?
|
Drug Interactions | 1 | 2012 | 1415 | 0.070 |
Why?
|
Time Factors | 6 | 2009 | 39928 | 0.070 |
Why?
|
Heroin | 1 | 2007 | 119 | 0.070 |
Why?
|
Neuropsychological Tests | 2 | 2013 | 7029 | 0.070 |
Why?
|
Substance Abuse, Intravenous | 1 | 2011 | 530 | 0.070 |
Why?
|
Disease Progression | 1 | 2024 | 13483 | 0.070 |
Why?
|
Cerebellum | 1 | 2014 | 1500 | 0.070 |
Why?
|
Anorexia Nervosa | 2 | 1992 | 1361 | 0.070 |
Why?
|
Injections, Intravenous | 2 | 2011 | 1379 | 0.070 |
Why?
|
Oxidative Stress | 1 | 1997 | 3109 | 0.060 |
Why?
|
Heart Rate | 3 | 2002 | 4189 | 0.060 |
Why?
|
Self Report | 1 | 2017 | 3717 | 0.060 |
Why?
|
Animals | 8 | 2022 | 168245 | 0.060 |
Why?
|
Methadone | 1 | 2007 | 321 | 0.060 |
Why?
|
Excitatory Amino Acid Antagonists | 2 | 1997 | 448 | 0.060 |
Why?
|
Pain, Intractable | 1 | 2006 | 132 | 0.060 |
Why?
|
Color Perception | 1 | 2006 | 212 | 0.060 |
Why?
|
Education | 1 | 2008 | 534 | 0.060 |
Why?
|
Patient Compliance | 1 | 2015 | 2686 | 0.060 |
Why?
|
Behavior, Animal | 1 | 2012 | 1877 | 0.060 |
Why?
|
Leptin | 1 | 2012 | 1593 | 0.060 |
Why?
|
Syndrome | 2 | 2022 | 3266 | 0.060 |
Why?
|
Oxygen | 3 | 2012 | 4220 | 0.060 |
Why?
|
Buprenorphine | 1 | 2011 | 655 | 0.060 |
Why?
|
Central Nervous System Stimulants | 2 | 2006 | 1176 | 0.060 |
Why?
|
Single-Blind Method | 1 | 2007 | 1571 | 0.060 |
Why?
|
Prevalence | 2 | 2016 | 15689 | 0.060 |
Why?
|
Public Policy | 1 | 2007 | 559 | 0.050 |
Why?
|
Depression | 2 | 2021 | 8101 | 0.050 |
Why?
|
Heterosexuality | 1 | 2005 | 309 | 0.050 |
Why?
|
Schizophrenic Psychology | 3 | 1999 | 1646 | 0.050 |
Why?
|
Raclopride | 5 | 2002 | 101 | 0.050 |
Why?
|
Schizotypal Personality Disorder | 1 | 2004 | 290 | 0.050 |
Why?
|
Streptothricins | 1 | 2022 | 5 | 0.050 |
Why?
|
Receptors, Adrenergic, alpha-1 | 1 | 2002 | 43 | 0.050 |
Why?
|
Bipolar Disorder | 2 | 2011 | 5088 | 0.050 |
Why?
|
Lipids | 1 | 2013 | 3341 | 0.050 |
Why?
|
Receptors, Adrenergic, alpha-2 | 1 | 2002 | 69 | 0.050 |
Why?
|
Genetic Predisposition to Disease | 2 | 2021 | 17859 | 0.050 |
Why?
|
Photic Stimulation | 3 | 2013 | 1971 | 0.050 |
Why?
|
3,4-Dihydroxyphenylacetic Acid | 1 | 2001 | 63 | 0.050 |
Why?
|
Young Adult | 5 | 2021 | 59054 | 0.050 |
Why?
|
Blood Pressure | 3 | 2002 | 8476 | 0.050 |
Why?
|
Dyskinesia, Drug-Induced | 1 | 2002 | 165 | 0.050 |
Why?
|
Sympathetic Nervous System | 1 | 2004 | 518 | 0.050 |
Why?
|
Health Policy | 1 | 2013 | 2680 | 0.050 |
Why?
|
Thirst | 1 | 2001 | 42 | 0.050 |
Why?
|
Medulla Oblongata | 1 | 2022 | 248 | 0.050 |
Why?
|
Image Processing, Computer-Assisted | 5 | 2011 | 8964 | 0.040 |
Why?
|
Task Performance and Analysis | 1 | 2004 | 760 | 0.040 |
Why?
|
Radioimmunoassay | 1 | 2001 | 866 | 0.040 |
Why?
|
N-Methylaspartate | 2 | 1998 | 231 | 0.040 |
Why?
|
Feeding Behavior | 1 | 2012 | 3187 | 0.040 |
Why?
|
Receptors, Dopamine D2 | 2 | 2002 | 485 | 0.040 |
Why?
|
Memory | 1 | 2009 | 2180 | 0.040 |
Why?
|
Receptors, Dopamine | 1 | 2000 | 296 | 0.040 |
Why?
|
Time | 1 | 2001 | 544 | 0.040 |
Why?
|
Hunger | 1 | 2001 | 205 | 0.040 |
Why?
|
Illness Behavior | 1 | 2018 | 23 | 0.040 |
Why?
|
Catechols | 1 | 1999 | 62 | 0.040 |
Why?
|
Cognition Disorders | 2 | 2006 | 3975 | 0.040 |
Why?
|
Serotonin | 1 | 2003 | 1040 | 0.040 |
Why?
|
Parkinson Disease, Secondary | 1 | 1999 | 122 | 0.040 |
Why?
|
Tritium | 1 | 1999 | 707 | 0.040 |
Why?
|
Monoamine Oxidase | 1 | 1999 | 180 | 0.040 |
Why?
|
Neurotransmitter Agents | 1 | 2022 | 665 | 0.040 |
Why?
|
Neural Inhibition | 1 | 2002 | 589 | 0.040 |
Why?
|
Fluphenazine | 1 | 1998 | 35 | 0.040 |
Why?
|
Vasodilation | 1 | 2002 | 961 | 0.040 |
Why?
|
Placebos | 1 | 2002 | 1661 | 0.040 |
Why?
|
Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 1066 | 0.040 |
Why?
|
Body Temperature | 1 | 2001 | 779 | 0.040 |
Why?
|
Fentanyl | 1 | 2001 | 435 | 0.040 |
Why?
|
Hair | 1 | 2001 | 497 | 0.040 |
Why?
|
Chronic Disease | 2 | 2011 | 9304 | 0.040 |
Why?
|
Brain Stem | 1 | 2022 | 858 | 0.030 |
Why?
|
Smoking | 1 | 2013 | 9048 | 0.030 |
Why?
|
Follow-Up Studies | 3 | 2005 | 39067 | 0.030 |
Why?
|
Synaptic Transmission | 1 | 2002 | 1171 | 0.030 |
Why?
|
Rats | 1 | 2012 | 23707 | 0.030 |
Why?
|
Truth Disclosure | 1 | 2000 | 433 | 0.030 |
Why?
|
Adolescent | 8 | 2022 | 88173 | 0.030 |
Why?
|
Regional Blood Flow | 1 | 1999 | 1486 | 0.030 |
Why?
|
Statistics, Nonparametric | 1 | 2001 | 2850 | 0.030 |
Why?
|
Salicylamides | 3 | 1999 | 33 | 0.030 |
Why?
|
Personality | 1 | 1998 | 554 | 0.030 |
Why?
|
Energy Metabolism | 1 | 2006 | 2873 | 0.030 |
Why?
|
Phencyclidine | 1 | 1994 | 60 | 0.030 |
Why?
|
Estrogens | 1 | 2001 | 1519 | 0.030 |
Why?
|
Respiration | 1 | 2001 | 1657 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2012 | 22079 | 0.030 |
Why?
|
Sex Factors | 2 | 2013 | 10534 | 0.030 |
Why?
|
Secondary Prevention | 2 | 2012 | 1473 | 0.030 |
Why?
|
Hypoglycemia | 1 | 2001 | 884 | 0.030 |
Why?
|
Positron-Emission Tomography | 2 | 2014 | 6475 | 0.030 |
Why?
|
Depressive Disorder, Major | 1 | 2011 | 4757 | 0.030 |
Why?
|
Cerebral Cortex | 1 | 2008 | 5764 | 0.030 |
Why?
|
Cognition | 2 | 2022 | 6971 | 0.030 |
Why?
|
Synapses | 1 | 2002 | 1762 | 0.030 |
Why?
|
Administration, Sublingual | 1 | 2011 | 58 | 0.020 |
Why?
|
Aged | 3 | 2021 | 168773 | 0.020 |
Why?
|
Massachusetts | 1 | 2003 | 8826 | 0.020 |
Why?
|
Risk Factors | 2 | 2016 | 73999 | 0.020 |
Why?
|
Aging | 1 | 2008 | 8686 | 0.020 |
Why?
|
Carbon Radioisotopes | 2 | 2000 | 562 | 0.020 |
Why?
|
Recurrence | 1 | 2020 | 8466 | 0.020 |
Why?
|
Infant | 1 | 2009 | 36179 | 0.020 |
Why?
|
Military Personnel | 1 | 2016 | 1245 | 0.020 |
Why?
|
Anxiety | 1 | 2021 | 4558 | 0.020 |
Why?
|
Acute Disease | 2 | 2007 | 7230 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2018 | 7813 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2000 | 14661 | 0.010 |
Why?
|
Hot Temperature | 1 | 2011 | 1439 | 0.010 |
Why?
|
Corpus Striatum | 2 | 2002 | 1235 | 0.010 |
Why?
|
Length of Stay | 1 | 1998 | 6410 | 0.010 |
Why?
|
Drug Administration Schedule | 2 | 2004 | 4848 | 0.010 |
Why?
|
Pyruvic Acid | 1 | 2004 | 203 | 0.010 |
Why?
|
Phenotype | 1 | 2021 | 16588 | 0.010 |
Why?
|
Wounds and Injuries | 1 | 2016 | 2483 | 0.010 |
Why?
|
Pain Measurement | 1 | 2013 | 3546 | 0.010 |
Why?
|
Incidence | 1 | 2001 | 21308 | 0.010 |
Why?
|
Linear Models | 1 | 2012 | 5861 | 0.010 |
Why?
|
Family | 1 | 1992 | 3189 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2021 | 15863 | 0.010 |
Why?
|
Frontal Lobe | 1 | 2007 | 1419 | 0.010 |
Why?
|
Functional Laterality | 1 | 2007 | 2251 | 0.010 |
Why?
|
Glucose | 2 | 2004 | 4342 | 0.010 |
Why?
|
Retrospective Studies | 2 | 2020 | 80414 | 0.010 |
Why?
|
Radioligand Assay | 1 | 2000 | 366 | 0.010 |
Why?
|
Reaction Time | 1 | 2006 | 2076 | 0.010 |
Why?
|
Adaptation, Physiological | 1 | 2006 | 1299 | 0.010 |
Why?
|
Hippocampus | 2 | 2004 | 3748 | 0.010 |
Why?
|
Neurons | 1 | 1998 | 9436 | 0.010 |
Why?
|
Basal Ganglia Diseases | 1 | 1999 | 145 | 0.010 |
Why?
|
Hospitalization | 1 | 1998 | 10692 | 0.010 |
Why?
|
Models, Biological | 1 | 2014 | 9461 | 0.010 |
Why?
|
Psychoses, Substance-Induced | 1 | 1998 | 99 | 0.010 |
Why?
|
Fear | 1 | 2006 | 1471 | 0.010 |
Why?
|
Prognosis | 1 | 1998 | 29547 | 0.010 |
Why?
|
Personality Assessment | 1 | 1998 | 650 | 0.010 |
Why?
|
Prospective Studies | 1 | 2001 | 54304 | 0.010 |
Why?
|
Choline | 1 | 1998 | 514 | 0.010 |
Why?
|
Creatine | 1 | 1998 | 427 | 0.010 |
Why?
|
Aspartic Acid | 1 | 1998 | 576 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2021 | 58838 | 0.010 |
Why?
|
Patient Care Team | 1 | 2006 | 2517 | 0.010 |
Why?
|
Anxiety Disorders | 1 | 2006 | 2716 | 0.010 |
Why?
|
Brain Chemistry | 1 | 1998 | 959 | 0.010 |
Why?
|
Human Growth Hormone | 1 | 1999 | 638 | 0.010 |
Why?
|
Radiography | 1 | 2004 | 6963 | 0.010 |
Why?
|
Binding Sites | 1 | 2002 | 6039 | 0.010 |
Why?
|
Reference Values | 1 | 2000 | 4921 | 0.010 |
Why?
|
Family Therapy | 1 | 1992 | 213 | 0.010 |
Why?
|
Prefrontal Cortex | 1 | 1998 | 2218 | 0.000 |
Why?
|
Child | 2 | 2006 | 80070 | 0.000 |
Why?
|
Health Status | 1 | 1998 | 4071 | 0.000 |
Why?
|
Diagnosis, Differential | 1 | 1999 | 12967 | 0.000 |
Why?
|
Treatment Outcome | 2 | 1999 | 64583 | 0.000 |
Why?
|